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Aim. Based on the previously established method, we developed a better and stable animal model of type 2 diabetes mellitus by
high-fat diet combined with multiple low-dose STZ injections. Meanwhile, this new model was used to evaluate the antidiabetic
eﬀect of berberine. Method. Wistar male rats fed with regular chow for 4 weeks received vehicle (control groups), rats fed with
high-fat diet for 4 weeks received diﬀerent amounts of STZ once or twice by intraperitoneal injection (diabetic model groups),
and diabetic rats were treated with berberine (100mg/kg, berberine treatment group). Intraperitoneal glucose tolerance test and
insulin tolerance test were carried out. Moreover, fasting blood glucose, fasting insulin, total cholesterol, and triglyceride were
measured to evaluate the dynamic blood sugar and lipid metabolism. Result. The highest successful rate (100%) was observed
in rats treated with a single injection of 45mg/kg STZ, but the plasma insulin level of this particular group was signiﬁcantly
decreased, and ISI has no diﬀerence compared to control group. The successful rate of 30mg/kg STZ twice injection group was
signiﬁcantly high (85%) and the rats in this group presented a typical characteristic of T2DM as insulin resistance, hyperglycemia,
and blood lipid disorder. All these symptoms observed in the 30mg/kg STZ twice injection group were recovered by the treatment
of berberine. Conclusion. Together, these results indicated that high-fat diet combined with multiple low doses of STZ (30mg/kg
at weekly intervals for 2 weeks) proved to be a better way for developing a stable animal model of type 2 diabetes, and this new
model may be suitable for pharmaceutical screening.
Copyright © 2008 Ming Zhang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Now there has been a tragic increase in diabetes across
the world, paralleling the overweight and obesity epidemic.
There are 95 percent of those people belonging to type 2
diabetes. Therefore, it is great urgency to ﬁnd better treat-
ments and novel prevention strategies for type 2 diabetes. To
accomplish this goal, appropriate experimental models are
consideredasessentialtoolsforunderstandingthemolecular
basis, pathogenesis of the vascular and neural lesions,
actions of therapeutic agents, and genetic or environmental
inﬂuences that increase the risks of type 2 diabetes.
Although there are numerous animal models (natural as
well as developed) available for the study of type 2 diabetes
[1–4], the pattern of disease establishment and progress in
most of them did not appear to be similar to the clinical
situation in humans. Thus, there is a continued quest among
the investigators with respect to the establishment of better
animal model for type 2 diabetes by adjusting the existing
methods, developing new methodologies, or a combination
of both.
Many studies have reported that the rats fed with high-
fat diet (HFD) develop insulin resistance but not frank
hyperglycemiaordiabetes [5–7].ItissuggestedthattheHFD
might be a better way to initiate the insulin resistance which
is one of the important features of type 2 diabetes. At the
same time, streptozotocin (STZ) is widely used to repro-
ducibly induce both insulin-dependent and noninsulin-
dependent diabetes mellitus presently by inducing β cell
death through alkylation of DNA [8]. Although high-dose
STZ severely impairs insulin secretion mimicking type 1
diabetes, low-dose STZ has been known to induce a mild
impairment of insulin secretion which is similar to the
feature of the later stage of type 2 diabetes [1, 2]. Therefore,
investigators have started to develop a rat model by feeding
the animal with high-fat diet following low-dose STZ that
would closely mimic the natural history of the disease events
(from insulin resistance to β cell dysfunction) as well as2 Experimental Diabetes Research
metabolic characteristics of human type 2 diabetes [1, 2, 4].
The successful establishment of such a model would be
cheaper, easily accessible, and practical for the investigation
as well as testing of various compounds for the treatment
of type 2 diabetes. Although the appearance of the type 2
diabetes pattern was achieved by combining the feeding of
HFD and low dose of STZ treatments in nongenetic, out-
bred rats, the injection dose of STZ and its methodologies
were not consistent in those studies. Others reported that
STZ may also be given in multiple low doses. It has been
extensively used in the development of type 1 diabetes in
rats and mice to study immune response in pancreas, since
the multiple low-dose injections of STZ could induce a
gradual, autoimmune destruction of β cells instead of the
rapiddestructioninducedbyasinglehigh-doseinjection[9–
14]. However, it has not been reported whether the high-fat
diet has synergistic eﬀect on accelerating the development of
type 2 diabetes with multiple low doses of STZ.
The purpose of the present study is to develop an
appropriate, stable animal model which is analogous to
the human type 2 diabetes mellitus through a com-
bination of high-fat diet with multiple low-dose STZ
injections. As a result, we provide a suitable animal
model to understand the possible cellular and molec-
ular mechanisms of type 2 diabetes. Meanwhile, the
treatment has been conducted. Berberine (C20H18C1NO4)
is the major active constituent of Rhizoma coptidis,
chemically named 5,6-Dihydro-9,10-dimethoxybenzo(g)-
1,3-dioxolobenzo(5,6a) quinolizine chloride. It was com-
monly used to treat diarrhea as an antimicrobial agent
before. Recently, it has been demonstrated that berberine is
available for the treatment of diabetes patients [12–15]. In
the present study, we will provide berberine to this model to
evaluate whether it could cure the diabetes induced by high-
fatdietcombinedwithnewmodelsofmultiplelow-doseSTZ
injections.
2. MATERIALS AND METHODS
2.1. Materials
STZ was purchased from Sigma, insulin was purchased
from Eli Lilly, Changchun, China; glucose, total cholesterol
(TC), and triglyceride (TG) test kits were obtained from
Beijing BHKT Clinical Reagent Co., Ltd, Beijing, China;
iodine [125I]insulin radioimmunoassay kit was purchased
from Tianjing Nine Tripods Medical & Bioengineering Co.,
Ltd, Tianjing, China; Other reagents were purchased from
Beijing General Chemical Reagent Factory, Beijing, China.
Berberine was a gift from Northeast drug factory.
2.2. Experimentalprotocol
Male Wistar rats (200–250g) were purchased from the
Experimental Animal Holding of Jilin University. The ani-
mals were housed in standard polypropylene cages (three
rats/cage) and maintained under controlled room tem-
perature and humidity with 12/12-hour light-dark cycle.
Regular chow consisting of 5% fat, 53% carbohydrate, 23%
protein, with total caloriﬁc value 25kJ/kg and high-fat diet
consisting of 22% fat, 48% carbohydrate, and 20% protein
with total caloriﬁc value 44.3kJ/kg were ordered from the
stoyer center of Experimental Animal Holding. Experiments
were conducted in the following three sections.
2.2.1. Firstsection
100Wistarratswererandomlydividedinto5groups:control
group (CON1), model group 1 (DM1), model group 2
(DM2), model group 3 (DM3), and model group 4 (DM4);
control group was fed with regular chow, and other four
groups were given high-fat diet for 4 weeks; four model
groups were injected intraperitoneally (IP) with diﬀerent
doses of STZ (STZ was injected only once, DM1: 25mg/kg;
DM2: 30mg/kg; DM3: 35mg/kg; DM4: 45mg/kg), while the
c o n t r o lr a t sw e r eg i v e nv e h i c l ec i t r a t eb u ﬀer (pH 4.4) in a
dose volume of 0.25mL/kg IP, respectively. The body weight
and food intake were recorded every week. After 8 weeks of
STZinjection,alltheratswerefastedfor12hours;thefasting
blood glucose (FBG) analysis was carried out. The successful
rate was calculated. The fasting blood insulin (FINS) was
measured; intraperitoneal glucose tolerance test (IPGTT)
and insulin tolerance test (ITT) were carried out in control
and highest successful rate model group.
2.2.2. Secondsection
60 Wistar rats were randomly divided into 3 groups: control
group (CON2), model group 5 (DM5), and model group
6 (DM6); control group was fed with regular chow, and
other two groups were given high-fat diet for 4 weeks; two
model groups were injected IP with a low dose of STZ
(STZ was injected twice, DM5: 25mg/kg; DM6: 30mg/kg).
After one week, FBG was measured, the rats with FBG <
7.8mmol/L were injected with STZ again (DM5: 25mg/kg;
DM6: 30mg/kg), while the control rats were given vehicle
citrate buﬀer (pH 4.4) in a dose volume of 0.25mL/kg, IP,
respectively. The body weight and food intake were recorded
every week. After 8 weeks of STZ injection, all the rats were
fasted for 12 hours, FBG was carried out. The successful
rate was calculated. Intraperitoneal glucose tolerance test
(IPGTT) and insulin tolerance test (ITT) were carried out
in control and highest successful rate model group.
2.2.3. Thirdsection
100Wistarratswererandomlydividedinto5groups:control
group (CON3), control plus STZ injection group (C-STZ),
high-fat diet group (HFD), high-fat diet plus STZ injection
group (HFD-STZ), Berberine treated high-fat diet plus STZ
injection group (BER); control group and control plus STZ
injection group were fed with regular chow, and other three
groupsweregivenhigh-fatdietfor4weeks;theC-STZ,HFD-
STZ groups and BER group were injected IP with a low
dose of STZ (according to the second section, choosing the
dose of the group with higher successful rate: 30mg/kg).
After one week, FBG was measured in these three groups,
the rats with FBG < 7.8mmol/L were injected with STZMing Zhang et al. 3
again (30mg/kg), while the control rats were given vehicle
citrate buﬀer (pH 4.4) in a dose volume of 0.25mL/kg, IP,
respectively. The fasting blood glucose was measured every
week. After 4 weeks of STZ injection, the rats with the fasting
blood glucose of ≥7.8mmol/L twice or with nonfasting
blood glucose of ≥11.1mmol/L were considered diabetic.
Berberine (100mg/kg body weight) was administered orally
as suspension by mixing with vehicle 1% Na-CMC at a dose
volume of 0.5mL/kg body weight of rats in treatment group
for another 4 weeks. The body weight and food intake of
the animals were also measured. The rats were allowed to
continue to feed on their respective diets until the end of
the study. At the end of the study, IPGTT and ITT were
conductedintheﬁvegroups;fastingplasmawascollectedfor
further measurement of insulin, TG, TC, and glucose. The
insulin sensitivity index (ISI) was calculated according to the
fasting insulin and glucose concentration.
2.3. MeasurementofFBG,FINS,TG,TC
Rats were fasted for 12–16 hours. Blood was collected from
tail vein; plasma was separated by centrifuge at 3500 × g
for 10 minutes. Fasting blood glucose (GOD-POD, glucose
oxidase-peroxidase), TC (CHOD-POD, cholesterol oxidase
peroxidase), and TG (GPO-POD, glycerol-phosphoric acid
oxidase peroxidase) were measured by using commercially
available colorimetric diagnostic kits according to the
instruction. Plasma insulin was assayed by RIA according to
the instruction.
2.4. Diabeticmodelsuccessfulrateand
insulinsensitivityindex
Diabetic model successful rate referred to the percentage of
diabetic rats in the group. The glucose level and insulin level
of the same rat were measured and its insulin sensitivity
index (ISI) was calculated as Ln(FBG × FINS)
−1.
2.5. Intraperitonealglucosetolerancetest
After an overnight fast (12–16 hours), the rats were IP
injected with 40% glucose (2g/kg body weight). Blood
samples were collected from the tail at 0, 30, 60, and 120
minutes for measurement of glucose.
2.6. Insulintolerancetest
Insulin (0.75IU/kg) was administered by intraperitoneal
injection and blood samples were collected at 0, 30, 60, and
120 minutes for the measurement of plasma glucose. The
value is presented as a percentage of initial plasma glucose
level.
2.7. Statisticalanalysis
The data are reported as mean ± SEM (n = 17–20/group).
Statistical analysis was performed by one way ANOVA.
P<. 05 was considered a statistical signiﬁcance between
control and experimental groups.
Table 1: The diabetic successful rate and FBG level in the groups of
the ﬁrst section.
GROUP NN 1 FBG (mmol/L) DSR
CON1 20 — 5.18 ±0.55 —
DM1 20 2 5.54 ±0.99 10%
DM2 20 7 7.92 ±1.37 35%
DM3 20 8 8.48 ±1.53 40%
DM4 20 20 24.5 ± 3.75∗ 100%
N: number of rats in each group; N1: number of rats with FBG >
7.8mmol/L which were injected with STZ after 8 weeks, CON1: control
group;DM1:STZ25mg/kgIP;DM2:STZ30mg/kgIP;DM3:STZ35mg/kg
IP; DM4: STZ 45mg/kg IP; FBG: fasting blood glucose; DSR: diabetic
successful rate. ∗P<. 001 versus control group.
3. RESULTS
3.1. FBGanddiabeticsuccessfulratein
thegroupsoftheﬁrstsection
Table 1 illustratedthediabeticsuccessfulrate(DSR)andFBG
level in rats which were fed with high-fat diet combined
with STZ 25mg/kg, 30mg/kg, 35mg/kg, and 45mg/kg. As
demonstrated in Table 1, the successful rate in 25mg/kg,
30mg/kg, and 35mg/kg STZ injection groups was low (10%,
35%, and 40%, resp.). However, 45mg/kg STZ injection had
the highest successful rate (100%), its FBG level was also
signiﬁcantly high compared to control group (P<. 001).
3.2. IPGTT,ITT,andISIinthegroupsoftheﬁrstsection
Our data showed that 45mg/kg STZ injection (DM4) had
the highest successful rate and higher FBG level. Therefore,
IPGTT and ITT were carried out in DM4 and control groups
to measure glucose tolerance and insulin sensitivity. As
showninFigure 1(a),DM4showedhyperglycemiacompared
to control rats during 120 minutes after glucose injection.
The areas under the glucose curves (mmol/L·min) were sig-
niﬁcantly greater in the DM4 group compared with controls
[(4000 ± 153) mmol/L·min versus (967 ± 46) mmol/L·min,
P<. 001]. To investigate diﬀerences in insulin sensitivity,
we performed an ITT at diﬀerent time points (Figure 1(b)).
Insulin was given intraperitoneally and blood was collected
for the measurement of glucose. In control group, glucose
concentrations declined rapidly after insulin administration,
and the decrease became signiﬁcant by 30 minutes. However,
therewasnosigniﬁcantdiﬀerencebetweentheSTZ45mg/kg
injection group and control groups during ITT. This result
demonstrated that the rats after STZ 45mg/kg injection
were sensitive to insulin; the ISI also supported this point
(Table 2). All the data indicated that high-fat diet associated
with 45mg/kg STZ injection developed a diabetic model
w h i c hw a sp r o n et ot y p e1d i a b e t e sm e l l i t u s .
3.3. FBGanddiabeticsuccessfulratein
thegroupsofthesecondsection
Table 3 showed the diabetic successful rate (DSR) and FBG
level of the rats which were fed with high-fat diet combined4 Experimental Diabetes Research
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Figure 1: (a) Plasma glucose during intraperitoneal glucose tolerance test (IPGTT) in STZ (45mg/kg, IP) group (DM4) and control rats
after 8 weeks of injection. (b) Percentage of initial glucose level during insulin tolerance test (ITT) in DM4 and control groups after 8 weeks
of injection. Data shown are means ± SE (n = 20 rats/group per time point). ∗P<. 001, DM3 versus control, by t-test.
Table 2: FBG, FINS, and ISI in STZ (45mg/kg, IP) group and
control group.
Group N FBG (mmol/L) FINS (mIU/L) ISI
CON1 20 5.18 ±0.55 11.8 ±2.93 −3.85 ±0.27
DM4 20 24.5 ±3.75∗∗ 3.97 ±0.86∗ −4.10 ±0.32
CON1: control group; DM4: 8 weeks after STZ 45mg/kg IP once, N:
number of rats in each group; FBG: fasting blood glucose at 8 weeks after
STZ injection; ISI = ln (FBG × FINS)
−1; FINS: fasting plasma insulin level;
∗∗P<. 001, ∗P<. 05, DM4 versus control group.
withSTZ25mg/kg,30mg/kgtwiceinjection.Itwasobserved
thatthesuccessfulratein25mg/kgSTZtwiceinjectiongroup
was low (25%). However, the successful rate of 30mg/kg
STZ twice injection group was relatively high (85%), and
the number of diabetic rats has been stable until the end
of the study. FBG level of DM6 group was also signiﬁcantly
increased compared to control group (P<. 01).
3.4. IPGTTandITTinthegroupsofthesecondsection
Since 30mg/kg STZ twice injection group (DM6) had the
higher successful rate and higher FBG level, IPGTT and ITT
were performed further in this group at 4 weeks (Figure 2)
and 8 weeks (Figure 3) after STZ injection. As shown in
Figure 2(a), 4 weeks after STZ injection, the glucose level
in DM6 and control group reached the highest level at 30
minutes after glucose injection, and slowly decreased in the
following 90 minutes. But the glucose level in DM6 showed
hyperglycemia compared to control rats during 120 minutes.
The areas under the glucose curves (mmol/L·min) were
signiﬁcantly greater in the STZ injection group compared
with controls [(3278 ± 274) mmol/L·min versus (1103 ±
81) mmol/L·min, P<. 01]. Meanwhile at 8 weeks after
STZ injection (Figure 3(a)), the areas under the glucose
curves (mmol/L·min) were still signiﬁcantly greater in the
STZ injection group compared with controls [(4498 ± 333)
mmol/L·min versus (913 ± 47) mmol/L·min, P<. 001].
To investigate diﬀerences in insulin sensitivity, we performed
ITT after 4 weeks (Figure 2(b)) and 8 weeks (Figure 3(b))
STZ injections. We found that, after insulin administration
in control group, glucose concentrations declined rapidly;
however, the glucose concentrations declined slowly or
even not declined in DM6 group within 30 minutes. After
30 minutes, the slopes of these two curves were similar
(Figure 2(b)).However,the percentageofinitial glucoselevel
in DM6 was shown to be signiﬁcantly higher than that
of control group during 120 minutes. These changes were
still signiﬁcant after 8 weeks STZ injection (Figure 3(b)).
This result demonstrated that the rats after STZ 30mg/kg
twice injection presented insulin resistance. All these data
indicated that high-fat diet associated with 30mg/kg STZ
twice injection developed a diabetic model which was an
analogue to type 2 diabetes mellitus with insulin resistance
and hyperglycemia.
3.5. Changesofbodyweightandfoodintakein
30mg/kgSTZtwiceinjectiongroupand
controlgroups
According to the data shown above, 30mg/kg STZ twice
injection developed a diabetic rat model with insulin resis-
tance and hyperglycemia. Therefore, we measured the body
weight and food intake between this group and the control
group. As shown in Table 4, the body weight gain during
the study was not statistically diﬀerent between two groups.
Caloric intake of 30mg/kg STZ twice injection group was
signiﬁcantly higher compared to control group (P<. 05).Ming Zhang et al. 5
Table 3: The diabetic successful rate and FBG level in the groups of the second section.
Group NN 1 N2 N3 N4 N5 FBG (mmol/L) DSR
CON2 20 — — — — — 4.27 ±0.41 —
D M 5 2 0 02355 5 .93 ±0.93 25%
DM6 20 4 10 12 17 17 14.26 ±0.57∗ 85%
N:n u m b e ro fr a t si nt h egr o u p ;N1: number of rats with FBG > 7.8mmol/L at one week after once STZ injection; N2: number of rats with FBG > 7.8mmol/L
at one week after twice STZ injection; N3: number of rats with FBG > 7.8mmol/L at two weeks after twice STZ injection; N4: number of rats with FBG >
7.8mmol/L at three weeks after twice STZ injection; N5: number of rats with FBG > 7.8mmol/L at four weeks after twice STZ injection; FBG: fasting blood
glucose; DSR: diabeticsuccessful rate; CON2: control group; DM5: twice STZ 25mg/kg IP group; DM6: twice STZ 30mg/kg IP group; ∗P<. 01 versus control
group.
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Figure 2: (a) Plasma glucose during intraperitoneal glucose tolerance test (IPGTT) in STZ (30mg/kg, twice, IP) group (DM6) and control
rats after 4 weeks of injection. (b) Percentage of initial glucose level during insulin tolerance test (ITT) in DM6 and control group after 4
weeks of injection. Data shown are means ± SE (n = 17–20 rats/group per time point). ∗P<. 01, DM6 versus control, by t-test.
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Figure 3: (a) Plasma glucose during intraperitoneal glucose tolerance test (IPGTT) in STZ (30mg/kg, twice, IP) group (DM6) and control
rats after 8 weeks of injection. (b) Percentage of initial glucose level during insulin tolerance test (ITT) in DM6 and control group after 8
weeks injection. Data shown are means ± SE (n = 17–20 rats/group per time point). ∗P<. 001, DM6 versus control, by t-test.6 Experimental Diabetes Research
Table 4: Body weight and food intake of control group and DM6.
Week Body weight (g) Food intake (KJ/d)
CON2 DM6 CON2 DM6
1 272.3 ±4.9 272.5 ± 5.95 4 .5 ± 1.07 3 .6 ±1.1∗
2 291.6 ±5.5 294.3 ± 6.94 8 .2 ± 1.26 5 .4 ±2.2∗
3 294.4 ±6.3 296.9 ± 7.44 7 .7 ± 0.75 9 .3 ±0.7∗
4 300.6 ±5.8 304.4 ± 7.74 8 .8 ± 1.56 3 .1 ±1.3∗
5 306.4 ±7.1 314.9 ± 7.15 3 .4 ± 1.36 7 .5 ±1.2∗
6 329.4 ±7.5 334.2 ± 9.85 4 .9 ± 1.96 4 .1 ±1.7∗
7 356.2 ±8.1 363.1 ± 9.55 1 .9 ± 1.06 7 .0 ±0.6∗
8 374 ± 9.0 373.0 ± 9.45 1 .7 ± 1.06 9 .4 ±1.0∗
9 384.8 ±8.9 383.6 ±10.15 8 .6 ± 1.77 3 .4 ±4.2∗
10 385.2 ±8.9 379.2 ±11.06 0 .9 ± 2.29 1 .4 ±2.7∗
11 389.9 ±10.0 375.6 ±10.16 9 .2 ± 1.59 5 .3 ±4.0∗
12 415.6 ±11.8 382.1 ±17.37 2 .3 ± 3.69 9 .5 ±3.0∗
CON2:controlgroup;DM6:high-fatdietwithSTZ30mg/kgtwiceinjection
group. Values are means ± SE; N:n u m b e ro fr a t s ,∗P<. 05 versus control
group.
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Figure 4: Plasma glucose curve in STZ (30mg/kg, twice, IP) group
(DM6) from 3 weeks after STZ injection to the end of the study
(n = 17–20 rats).
3.6. Stabilityofexperimentaldiabeticmodel
From the data shown in the second section, 30mg/kg STZ
twice injection might develop a better type 2 diabetic rat
model. Therefore, in the third section we investigated the
stability of this experimental type 2 diabetic model.
As shown in Figure 4, the FBG of the model group has
been measured every week; this result indicated that the
hyperglycemia was stable around 14mmol/L from 4 weeks
after STZ injection to 8 weeks after STZ injection.
The biochemical parameter and ISI at the end of study
were presented in Table 5. As can be seen, the high-fat diet
groupincreasedthebodyweightsigniﬁcantlycomparedwith
control group; the body weight from STZ injected chow
diet rats had no signiﬁcant diﬀerence compared with control
group. High-fat diet group presented higher FINS, TG, and
TC levels, but there was no signiﬁcant diﬀerence in blood
glucose level compared with control groups. FBG, FINS,
TG, and TC of HFD-STZ group were signiﬁcantly increased
compared with control group, the ISI was much lower than
thecontrolgroup,whichindicatedthattheinsulinsensitivity
was remarkably decreased in HFD-STZ group compared
to the control group. Moreover, biochemical parameters of
the control plus STZ injection group were not signiﬁcantly
c h a n g e dc o m p a r e dt oc o n t r o lg r o u p .
3.7. Beneﬁcialeffectofberberineonthediabeticrats
Furthermore, we observed whether this animal model was
suitable for pharmaceutical research. As shown in Figure 5,
Berberine (100mg/kg) orally administration improved
impaired glucose tolerance, and enhanced insulin sensitivity.
After 4 weeks of treatment, the areas under the glucose
curves (mmol/L·min) were still signiﬁcantly lower in the
berberine treatment group compared with diabetes model
group [(2499 ± 167) mmol/L·min versus (3822 ± 344)
mmol/L·min, P<. 05]. In the treatment group, the glucose
concentration declined rapidly during ITT. Meanwhile,
berberine administration signiﬁcantly decreased FBG, TC,
and TG levels compared to diabetic model group (P<. 05),
the fasting insulin was changed but not signiﬁcantly, ISI
was higher than the model group, and the result indicated
that berberine improved insulin sensitivity and abnormal
blood lipid. The berberine treatment decreased the body
weight slightly but with no signiﬁcant diﬀerence compared
with HFD-STZ group (Table 5). This data also demonstrated
that the diabetic model we developed might be suitable for
pharmaceutical research.
4. DISCUSSION
Type 2 diabetes is a complex, heterogeneous, and polygenic
disease. There are many underlying factors that contribute
to the high blood glucose levels in these type 2 diabetes
patients. An important factor is the body’s resistance to
insulin, essentially ignoring its insulin secretions. A second
factor is the falling production of insulin by the β cells of
the pancreas. Therefore, an individual with type 2 diabetes
may have a combination of deﬁcient secretion and action
of insulin. Hence, an experimental animal model which
aims at mimicking the pathogenesis and clinical feature of
human type 2 diabetes mellitus should preferably have these
two traits. Among the animal models available, inherited
hyperglycaemia and/or obesity in certain strains have been
wildly used in the investigations, such as ob/ob mouse,
Zucker rats, and OLETF rats. However, those inbred diabetic
models are comparatively expensive and not easy to breed.
Thus, type 2 diabetic model developed in rodents has been
studied for reasons such as short generation time and
economic considerations.
Currently, many studies have reported that the high-fat
diet (HFD) feeding rats develop insulin resistance [5–7]. At
the same time, low-dose STZ has been known to induce
a mild impairment of insulin secretion which is similar
to the feature of the later stage of type 2 diabetes [1, 2].
Therefore, investigators have started to develop a rat model
by high-fat diet following low-dose STZ that would closely
mimic the natural history of the disease [1, 2, 4]. Although
the appearance of the type 2 diabetes pattern was achievedMing Zhang et al. 7
Table 5: The biochemical parameter and ISI in the groups of the third section.
Group CON3 C-STZ HFD HFD-STZ BER
N 20 20 20 17 17
Body weight (g) 415.6 ±11.8 397.9 ±14.2 477.3 ±23.1∗Δ 382.1 ±17.3 368.6 ±19.8
FBG (mmol/L) 4.49 ±0.41 5.25 ±0.44 5.56 ±0.52 14.79 ±0.32∗∗ 6.48 ±0.56Δ
FINS (mU/L) 11.03 ±1.68 12.04 ±0.26 19.64 ±6.83∗ 9.17 ±1.34 10.04 ±0.91
ISI −3.87 ±0.15 −3.93 ±0.20 −4.69 ±0.21∗ −4.87 ±0.15∗ −3.68 ±0.09Δ
TG (mmol/L) 0.66 ±0.09 0.63 ±0.08 1.91 ±0.33∗∗ 1.70 ±0.21∗∗ 0.96 ±0.17∗Δ
TC (mmol/L) 1.72 ±0.11 1.78 ±0.19 3.35 ±0.26∗∗ 2.99 ±0.53∗∗ 2.67 ±0.58∗
CON3: control group; C-STZ: regular chow feed group with STZ 30mg/kg twice IP; HFD: high-fat diet group; HFD-STZ: model group by high-fat diet with
STZ 30mg/kg twice IP; BER: berberine treatment group; FBG: fasting blood glucose; FINS: fasting blood insulin; ISI = ln(FBG×FINS)
−1;T G :t r i g l y c e r i d e ;
TC: total cholesterol. Values are means ± SE, ∗∗P<. 01, ∗P<. 05 versus control group, ΔP<. 05 versus HFD-STZ group.
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Figure 5: (a) Plasma glucose during intraperitoneal glucose tolerance test (IPGTT) in STZ (30mg/kg, twice, IP) group (HFD-STZ),
berberine trearment group (BER) and control rats (CON3) after 8 weeks injection. (b) Percentage of initial glucose level during insulin
tolerance test (ITT) in these three groups after 8 weeks injection. Data shown are means ± SE (n = 17–20 rats/group per time point).
∗P<. 01, versus control group, #P<. 05, versus HFD-STZ group.
by combining the feeding of HFD and low dose of STZ
treatments in nongenetic, out-bred rats, the injection dose
of STZ and its methodologies were not consistent in those
studies.
The purpose of the present study was to develop an
animal model of type 2 diabetes that would imitate the
natural history and the metabolic characteristics of the
human syndrome and be responsive to the pharmaceutical
treatment. On the other hand, the goal of the present
study was to develop an animal model which is neither
inheritednorgeneticallyobese,andwhichiseasilyaccessible,
fairly economical, and with high successful rate. The results
demonstrated that we had achieved our goals.
The primary attempts of the present study were to
identify the dose of STZ that was low enough to develop
type 2 diabetes models in HFD rats with higher successful
rate and without much insulin deﬁciency. The diﬀerent
doses of STZ (25, 30, 35, 45mg/kg, IP) were studied.
Injection of STZ (45mg/kg, IP) after 4 weeks of high-fat
diet caused frank hyperglycemia with 100% success rate,
which is consistent with literature reports [1]. Further, these
rats were insulin sensitive, presenting an insulin-deﬁcient
symptom as compared to the control rats. Thus, these fat-
fed rats with high dose of STZ (45mg/kg) were considered
resembling type 1 diabetes. In contrast, STZ (30mg/kg and
35mg/kg, IP) failed to generate a signiﬁcant hyperglycemia
in HFD-fed rats. Srinivasan et al. have reported the similar
results showing that STZ (25mg/kg, 35mg/kg, 45mg/kg,
and 55mg/kg, once injected) could be used to develop
diabetic model. Since the dose of STZ (25mg/kg) did not
produce signiﬁcant hyperglycemia, and fat-fed/STZ (45 and
55mg/kg, IP) diabetic rats exhibited fairly high glucose
and a drastic reduction in the body weights, they ﬁnally
chose 35mg/kg STZ injection as the optimum dose, but8 Experimental Diabetes Research
the successful rate of this method has not been reported
[2].
Our second study attempted to ﬁnd if multiple low doses
of STZ could achieve our goal (high successful rate and
performance of type 2 diabetes). Multiple low-dose STZ
injection to induce diabetes and its complication model have
been reported in many studies [9–14]. Multiple low doses
of STZ in rats and mice could induce a combination of
poisonous and immunological response presenting progres-
sively hyperglycemia. Investigator from Korea has reported
that male Sprague-Dawley rats showed rapid chemical
destruction of the pancreatic β cells when they were given
a single high-dose injection of STZ (80mg/kg, IP); interest-
ingly, multiple low-dose injections of STZ (20mg/kg for 5
consecutive days, IP) could induce a gradual, autoimmune
destruction of β cells [13]. Wright Jr. and Lacy reported
that rats receiving multiple low doses of STZ (25mg/kg
IP at weekly intervals for 3 weeks) only did not develop
diabetes. Immunologic adjuvants played the synergistic role
in prompting the induction of diabetes with multiple low
doses of STZ in rats [14]. Therefore, it can be proved
that multiple low doses of STZ acted to induce a gradual
destruction of β-cell. This might happen in decompensated
phase of type 2 diabetes. High-fat diet has been extensively
used to develop insulin resistance [5–7]. Therefore, high-fat
diet combined with multiple low dose of STZ might develop
a suitable type 2 diabetes animal model which presents
not only insulin resistance but also insulin deﬁciency. The
current study proved this point. Our data demonstrated that
multiple low doses of STZ (30mg/kg IP at weekly interval
for 2 weeks) produced frank hyperglycemia in HFD-fed rats
with highly successful rate, but did not produce the same
in regular chow-fed rats. The ISI and ITT all demonstrate
the insulin resistance of these diabetic rats. Hence, HFD
in combination with multiple low doses of STZ (30mg/kg,
twice injection at weekly interval) can be more considered to
characterize the pathophysiology of type 2 diabetes.
Furthermore, the diabetic model we developed produces
hyperglycemia around 14.5mmol/L, which is reasonable to
be treated by therapeutic compound as practiced clinically.
Therapeutically, it is diﬃcult to reduce elevated blood
glucose except for administration of insulin. Berberine,
the major active constituent of Rhizoma coptidis, is used
clinically in the treatment of diarrhea as an antimicrobial
agent. Early as 1986, investigators from china have started
to report the hypoglycemic eﬀect of berberine. In 1999,
Yuan reported that berberine exerted beneﬁcial eﬀect on
the treatment of diabetes clinically; other investigators also
proved its role in the treatment of type 2 diabetes in
clinic [15–18]. The mechanisms of the antidiabetic eﬀect of
berberine involved multiple factors. Yin et al. reported that
berberine improved glucose metabolism through induction
of glycolysis in many cell lines including 3T3-L1 adipocytes,
L6 myotubes, C2C12 myotubes, and H4IIE hepatocytes,
which might be related to inhibition of glucose oxidation in
mitochondria [19, 20]. Others revealed that the underlying
mechanism for berberine improves insulin resistance and
lowers blood sugar possibly through activating the AMP-
activated protein kinase (AMPK) pathway [21]. It has
also been demonstrated that inhibiting phosphorylation of
IKKβ might be a cofactor of berberine in achieving its
anti-inﬂammation and insulin-resistance-improving eﬀects
[22]. The latest study also proved that berberine could
inhibit fructose-induced insulin resistance in rats possibly by
increasing the expression HNF-4α in liver [23]. HNF-4α is a
positive regulatorof PEPCK so anincrease ofHNF-4α would
resultinincreasedgluconeogenesis.Hence,weadministrated
berberine as antidiabetic drug in the present study, and
our result also demonstrated that berberine treatment could
decrease the insulin resistance and improve impaired glucose
tolerance. Meanwhile, we also found that berberine could
correct lipid metabolism disorders, which indicated that
the treatment of berberine might play an important role
in diabetic complication. Altogether, the diabetic model we
developed was suitable to investigate not only the pathogen-
esis but also the pharmaceutical selection. Meanwhile, the
current study considered the incidence of diabetes in the
group. This method will successfully produce type 2 diabetic
rat models, as well as provide the enough number of diabetic
ratsoncewhichwillmaketheinvestigationmoreconvincing.
Conclusively, our study demonstrates that a combination
of HFD and multiple low doses of STZ injection could
be eﬀectively used to generate a rat model that mimics
the natural history and metabolic characteristics of type 2
diabetes in humans. It was also useful in evaluating the
eﬀect of therapeutic compounds on the treatment of type 2
diabetes.
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